Swaminathan Maya, Holt Sarah K, Gore John L, Nyame Yaw A, Wright Jonathan, Shah Ami, Sparks Jeffrey A, Makris Una E, Grivas Petros, Suarez-Almazor Maria, Psutka Sarah, Singh Namrata
Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA.
Department of Urology, University of Washington, Seattle, WA.
Clin Genitourin Cancer. 2025 Aug;23(4):102369. doi: 10.1016/j.clgc.2025.102369. Epub 2025 Apr 30.
To evaluate the associations between rheumatoid arthritis (RA) and all-cause (ACM) and cancer-Specific mortality (CSM) in older adults with bladder cancer and examine how frailty may affect these associations.
Retrospective cohort study derived from the Surveillance Epidemiology and End Results (SEER) cancer registry and linked to Medicare claims data (SEER-Medicare). The cohort consisted of patients ≥ 65 years diagnosed with bladder cancer between 2004 and 2017. RA and frailty status were derived using validated administrative algorithms. ACM and CSM as derived from the SEER registry.
Frailty modified the relationship between RA and mortality outcomes (interaction P value for ACM: .002 and for CSM: .007). We observed that RA was associated with a higher risk of CSM (aHR 1.17, 95% CI, 1.01-1.35) and ACM (aHR 1.12, 95% CI, 1.05-1.20) in nonfrail patients. In frail patients with bladder cancer, RA was not independently associated with CSM (aHR 0.81, 95% CI, 0.62-1.06) or ACM (aHR 0.93, 95% CI, 0.83-1.05).
Frailty is associated with adverse health outcomes. As people are living longer, it is becoming increasingly prevalent among patients with chronic conditions such as RA. We observed that RA is associated with increased risk of ACM and CSM among nonfrail older adults with bladder cancer. The lack of an association between RA and mortality in frail patients with RA suggests that the effect of frailty on mortality may overpower the effect that RA may exert-this information can help prognosticate outcomes in patients with bladder cancer, RA, and frailty.
评估老年膀胱癌患者中类风湿性关节炎(RA)与全因死亡率(ACM)和癌症特异性死亡率(CSM)之间的关联,并研究虚弱如何影响这些关联。
这项回顾性队列研究源自监测、流行病学和最终结果(SEER)癌症登记处,并与医疗保险索赔数据(SEER - Medicare)相链接。该队列由2004年至2017年间诊断为膀胱癌的65岁及以上患者组成。RA和虚弱状态通过经过验证的管理算法得出。ACM和CSM源自SEER登记处。
虚弱改变了RA与死亡率结局之间的关系(ACM的交互P值:0.002,CSM的交互P值:0.007)。我们观察到,在非虚弱患者中,RA与较高的CSM风险(风险比[HR]为1.17,95%置信区间[CI]为1.01 - 1.35)和ACM风险(HR为1.12,95% CI为1.05 - 1.20)相关。在患有膀胱癌的虚弱患者中,RA与CSM(HR为0.81,95% CI为0.62 - 1.06)或ACM(HR为0.93,95% CI为0.83 - 1.05)无独立关联。
虚弱与不良健康结局相关。随着人们寿命延长,它在诸如RA等慢性病患者中越来越普遍。我们观察到,在非虚弱的老年膀胱癌患者中,RA与ACM和CSM风险增加相关。RA与虚弱的RA患者死亡率之间缺乏关联表明虚弱对死亡率的影响可能超过RA可能产生的影响——这一信息有助于预测膀胱癌、RA和虚弱患者的结局。